BenevolentAI Results Presentation Deck
Robust pipeline entirely generated by the Benevolent
Platform™
BEN-2293 | Atopic Dermatitis
BEN-8744 | Ulcerative Colitis
BEN-28010 | Glioblastoma Multiforme
BEN-9160 | Amyotrophic Lateral Sclerosis
Inflammatory Bowel Disease
Amyotrophic Lateral Sclerosis
Antiviral
Oncology
Oncology
Parkinson's Disease
Nonalcoholic Steatohepatitis (NASH)
Oncology
Parkinson's Disease
Fibrosis
Inflammation
Chronic Kidney Disease
Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Chronic Kidney Disease
BAI pipeline as at end-December 2022
+10 Exploratory stage programmes
Target ID
Chemistry &
Lead Opt
AstraZeneca
AstraZeneca
AstraZeneca
Preclinical
AstraZeneca
27.01.2021
AstraZeneca 17.05.2022
15.12.2021
06.10.2022
06.10.2022
Phase I
BenevolentAl Proprietary
Phase II
Highlights
• All pipeline programmes
generated using the Benevolent
Platform™
• BEN-2293: Phase Ila read out
Q1-2023
• BEN-8744: Novel target with
zero prior linkage to UC.
Delivered drug candidate
within 2 years from programme
initiation, starting Phase 1
H1-2023
• AstraZeneca: multi-year
Target-ID collaboration
expanded in Jan 2022 to
include systemic lupus
erythematosus & heart failure.
Benevolent 15View entire presentation